This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
All doses of Novo Nordisk’s blockbuster diabetes and obesity treatments are listed as available on the Food and Drug Administration’s drug shortage list as of Wednesday, raising the possibility that the medications could soon be taken off the list entirely, a development that could affect compounding pharmacies and patients relying on compounded drugs.
‘Dope’ is no longer heroin in an increasing number of our communities. The biggest change has been the gradual replacement of diacetylmorphine (heroin) by fentanyl and other synthetic opioids. Due in large part to the proliferation of anonymous chemical factories able to produce industrial volumes of inexpensive synthetic opioids without opium or other controlled precursors, fentanyl spilled into the United States, Canada, and Europe, heroin soon fell to market forces [1, 2].
Health tech investments are showing signs of resilience following the perilous lows of 2022 and 2023: Just this past month, two startups that analysts believe might be getting ready for IPOs raised more than $100 million in late-stage funding rounds. And deal volume hit a record high in the second quarter, largely from early-stage deals, according to a Silicon Valley Bank analysis.
The pharmaceutical industry is known for its complex regulatory environment and lengthy product development processes. One often overlooked aspect of this industry is the potential benefits of abandoned and expired patents. These patents can provide opportunities for companies to bring new products to market at a lower cost and with reduced development time.
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far, so we are determined to hang on for another couple of days. And why not? The alternatives — at least those we can identify — are not so appealing. And what better way to make the time fly than to keep busy.
Eli Lilly’s third-quarter sales and earnings were lower than expected, a rare stumble for the company that had consistently reported strong sales and beat earnings forecasts since demand for its blockbuster weight loss and diabetes drugs began booming. The company reported Wednesday overall revenue of $11.4 billion, lower than the $12.2 billion expected from analysts polled by Visible Alpha.
Sumagen Canada Inc, a biotech company based in both South Korea and Canada has partnered with CDMO Naobios to industrialise Sumagen’s human immunodeficiency virus (HIV) -1 vaccine candidate (SAV0001) at bench scale. First of its kind in human vaccine trials, SAV001 is a whole-killed and genetically modified HIV vaccine. During phase 1 of the clinical […] The post HIV vaccine candidate successfully optimised for industrial production appeared first on Pharmafile.
The STAT Diversity and Inclusion Committee presents STAT’s 2024 Diversity and Inclusion Report. Here, we share the self-reported gender and racial/ethnic demographics of our staff from STAT’s inception in 2015 through 2023, as well as our 2023 new hire demographics. STAT’s Inaugural Diversity and Inclusion Report, published last year, is available here.
The first confirmed human case of Clade Ib mpox in the UK has been detected in London, the UK Health Security Agency (UKHSA) has said. But it stressed that the risk to the UK population 'remains low'. And Steve Russell, NHS national director for vaccination and screening, said there were 'plans in place to expand […] The post First UK case of Clade IB mpox could prompt ‘quick vaccine expansion’ appeared first on The Pharmacist.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Axonis Therapeutics, a biotech company that has been quietly operating for the last five years, has raised $115 million after retooling its drug pipeline. The startup announced Wednesday that it closed a Series A round led by Cormorant Asset Management and venBio Partners — its first major financing after subsisting on a string of seed financing deals.
National living wage and employer national insurance contributions will increase from April 2025, the chancellor has announced in today's Autumn Budget. But pharmacy leaders have expressed concern that pharmacies will not be able to meet these 'looming increases' unless pharmacy funding is uplifted in the next contract. Increases to living wage and national insurance contributions […] The post National living wage increase will be 'huge additional cost' for pharmacies appeared fi
Semaglutide, better known as Ozempic and Wegovy, helped alleviate pain from knee osteoarthritis and improve function in patients with severe obesity, a new study found. The results of the 68-week trial were published in the New England Journal of Medicine , and could pave the way for a future FDA approval of GLP-1 receptor agonists for the joint-degrading condition.
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
Novartis says FDA approval for frontline use of its leukaemia drug Scemblix will boost the number of eligible patients four-fold, as it hunts blockbuster sales
Pharma Tech Industries, a pharmaceutical manufacturing and packaging solutions contractor for wellness products and medical devices, has announced the appointment of their new chief executive officer Darrin T Schellin. “I am honoured to join Pharma Tech Industries at such an exciting time in its journey,” said Mr Schellin. “As I step into this leadership role, […] The post Darrin Schellin appointed new CEO at Pharma Tech Industries appeared first on Pharmafile.
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
The partners no longer intend to develop Zurzuvae for one of the most common forms of depression, citing the time and cost of running new studies that would satisfy the FDA.
Discover how GenAI is leveraging AI technology to streamline R&D processes, ensuring trusted data and accelerating drug discovery timelines while reducing costs.
Third quarter Mounjaro and Zepbound sales, while up substantially versus the same period last year, grew little compared to the second quarter amid inventory decreases in the U.S.
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned patients may still experience "variability" filling their prescriptions.
The burden of diagnosed prevalent cases of primary open angle glaucoma (POAG) (including normal tension glaucoma (NTG)) is forecast to increase at an annual growth rate (AGR) of 1 per cent from around 9.1 million cases in 2023 to 10 million cases in 2033 in the seven major markets (7MM*), according to GlobalData. GlobalData’s latest report, ‘Glaucoma: Epidemiology Forecast to 2033’, reveals that the increase is partly attributed to increased disease awareness and improved diagnostic testing acro
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Discover how leveraging AI can help biopharma companies future-proof their operations and strategies. Learn about innovative AI strategies that can drive success in the biopharma industry.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content